article · FUDMA Journal of Sciences
Introduction: Escherichia coli (E. coli) is a Gram-negative that can become true pathogenic. Extended-spectrum Beta-lactamases (ESBLs) are enzymes that make bacteria resistant to antibiotics, posing risks for infections and requiring strict infection control measures. Methodology: A hospital-based study in Southwestern Nigeria (August–November 2020) analyzed 105 Escherichia coli isolates using biochemical tests, EMB agar, and PCR for molecular identification. Antibiotic susceptibility was assessed via the Kirby-Bauer method, interpreted using CLSI criteria. Molecular analysis identified blaCTX, blaSHV, and blaTEM genes. Data underwent descriptive analysis and Chi-square testing, with a p-value <0.05 considered significant, highlighting associations between variables and antibiotic resistance genes. Results: It was discovered that 35 out of 105 (33.3%) clinical Escherichia coli isolates were confirmed to be Escherichia coli isolates using the TEcol primer. At least one of the three (3) genes of ESBL was screened for in 60% of the confirmed Escherichia coli isolates; 17.1%, 37.1% and 40% of the isolates had SHV, TEMH and CTX-M genes respectively. There was 100% resistivity of the extended-spectrum beta-lactamases producing Escherichia coli isolates to Amoxycillin/Clavulanic acid, Meropenem, Oxacillin, Ceftazidime and Cefepime; 33.3%, 47.6%, 61.9%, 71.4% and 81% of the extended-spectrum beta-lactamases-producing isolates were resistant to Imipenem, Chloramphenicol, Levofloxacin, Ciprofloxacin and Cefoxitin respectively. Significance of Results: There is prevalence of blaCTX-M-positive extended-spectrum beta-lactamases isolates, and increasing spread of extended-spectrum beta-lactamases-producing clinical Escherichia coli isolates in Southwest Nigeria. Conclusion: There is existence and increasing production of Extended-spectrum Beta-lactamases in some clinical isolates of Escherichia coli.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.33003/fjs-2025-0908-3057
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.